Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 67576A100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| BlackRock, Inc. 13G/A Amendment 6 | 7.0% |
7/29/2026
Event 6/30/2026
|
|
|
Deep Track Capital, LP
13G/A
Amendment 1
|
9.5% |
5/15/2026
Event 3/31/2026
|
|
| Deep Track Capital, LP | 9.5% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 9.5% | ||
| David Kroin | 9.5% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
3.2% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | ||
| VHCP Co-Investment Holdings III, LLC | 3.2% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 3.2% | ||
| VHCP Management III, LLC | 3.2% | ||
| VHCP Management EG, LLC | 3.2% | ||
| Nimish Shah | 3.2% | ||
| Bong Y. Koh | 3.2% | ||
|
Deep Track Capital, LP
13G
|
5.1% |
2/10/2026
Event 2/5/2026
|
|
| Deep Track Capital, LP | 5.1% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.1% | ||
| David Kroin | 5.1% | ||
|
Deep Track Capital, LP
13G/A
Amendment 3
|
4.3% |
2/10/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 4.3% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 4.3% | ||
| David Kroin | 4.3% | ||
| Summer Road LLC 13G | 5.7% |
12/8/2025
Event 12/4/2025
|
|
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 2
|
7.3% |
11/14/2025
Event 9/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 7.3% | ||
| VHCP Co-Investment Holdings III, LLC | 7.3% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 7.3% | ||
| VHCP Management III, LLC | 7.3% | ||
| VHCP Management EG, LLC | 7.3% | ||
| Nimish Shah | 7.3% | ||
| Bong Y. Koh | 7.3% | ||
|
Deep Track Capital, LP
13G/A
Amendment 2
|
6.2% |
11/14/2025
Event 9/30/2025
|
|
| Deep Track Capital, LP | 6.2% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.2% | ||
| David Kroin | 6.2% | ||
|
FMR LLC
13G/A
Amendment 1
|
15.0% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
| BlackRock, Inc. 13G/A Amendment 5 | 5.8% |
10/17/2025
Event 9/30/2025
|
|
|
FMR LLC
13G
|
12.3% |
7/8/2025
Event 6/30/2025
|
|
| FMR LLC | 12.3% | ||
| Abigail P. Johnson | 12.3% | ||
|
Deep Track Capital, LP
13G/A
Amendment 1
|
9.7% |
5/15/2025
Event 3/31/2025
|
|
| Deep Track Capital, LP | 9.7% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 9.7% | ||
| David Kroin | 9.7% | ||
| Opaleye Management Inc. 13G/A Amendment 6 | 2.8% |
2/14/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 27.1 k | $192 k |
| 2026 Q2 | 278 | 209 M | $2.24 B |
| 2026 Q1 | 289 | 207 M | $1.77 B |
| 2025 Q4 | 269 | 192 M | $2.33 B |
| 2025 Q3 | 232 | 188 M | $2.20 B |
| 2025 Q2 | 199 | 158 M | $1.46 B |
| 2025 Q1 | 206 | 138 M | $1.01 B |
| 2024 Q4 | 190 | 134 M | $1.14 B |
| 2024 Q3 | 176 | 140 M | $1.22 B |
| 2024 Q2 | 162 | 145 M | $995 M |
| 2024 Q1 | 156 | 126 M | $1.02 B |
| 2023 Q4 | 128 | 74.8 M | $300 M |
| 2023 Q3 | 122 | 40.5 M | $108 M |
| 2023 Q2 | 145 | 43.5 M | $193 M |
| 2023 Q1 | 136 | 40.6 M | $182 M |
| 2022 Q4 | 125 | 41.1 M | $115 M |
| 2022 Q3 | 141 | 42.8 M | $178 M |
| 2022 Q2 | 128 | 44.3 M | $178 M |
| 2022 Q1 | 137 | 43.5 M | $216 M |
| 2021 Q4 | 157 | 41.9 M | $291 M |
| 2021 Q3 | 152 | 44.5 M | $446 M |
| 2021 Q2 | 163 | 48.4 M | $686 M |
| 2021 Q1 | 164 | 47.2 M | $775 M |
| 2020 Q4 | 163 | 50.6 M | $1.05 B |
| 2020 Q3 | 114 | 39.8 M | $303 M |
| 2020 Q2 | 113 | 38.7 M | $322 M |
| 2020 Q1 | 102 | 28.5 M | $141 M |
| 2019 Q4 | 85 | 25.8 M | $102 M |
| 2019 Q3 | 86 | 23.3 M | $70.8 M |
| 2019 Q2 | 85 | 23.1 M | $102 M |
| 2019 Q1 | 76 | 22.4 M | $89.0 M |
| 2018 Q4 | 76 | 22.0 M | $87.9 M |
| 2018 Q3 | 84 | 21.8 M | $150 M |
| 2018 Q2 | 76 | 22.1 M | $149 M |
| 2018 Q1 | 71 | 20.5 M | $133 M |
| 2017 Q4 | 77 | 13.5 M | $60.1 M |
| 2017 Q3 | 82 | 15.6 M | $96.5 M |
| 2017 Q2 | 83 | 15.5 M | $144 M |
| 2017 Q1 | 84 | 19.0 M | $176 M |
| 2016 Q4 | 84 | 17.7 M | $148 M |
| 2016 Q3 | 79 | 18.8 M | $129 M |
| 2016 Q2 | 78 | 19.5 M | $96.4 M |
| 2016 Q1 | 66 | 20.9 M | $201 M |
| 2015 Q4 | 73 | 21.1 M | $197 M |
| 2015 Q3 | 72 | 22.0 M | $314 M |
| 2015 Q2 | 72 | 18.1 M | $380 M |
| 2015 Q1 | 57 | 13.3 M | $557 M |
| 2014 Q4 | 37 | 7.59 M | $179 M |
| 2014 Q3 | 35 | 7.22 M | $108 M |